Minerva Neurosciences, Inc. (NERV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.2962-0.0538 (-3.99%)

As of 3:44PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	1.3500
Open	1.3600
Bid	1.2900 x 3000
Ask	1.3000 x 2200
Day's Range	1.2900 - 1.3675
52 Week Range	1.2900 - 4.1150
Volume	307,092
Avg. Volume	654,187

Market Cap	55.376M
Beta (5Y Monthly)	1.07
PE Ratio (TTM)	N/A
EPS (TTM)	-0.8190
Earnings Date	Nov 01, 2021 - Nov 05, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-25% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NERV

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Minerva Neurosciences, Inc
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the continuing shift to software; biopharma capital allocation; rising ransomware attacks; and new coverage of Stem, Keysight, and Carlyle Group.
Rating
Fair Value
Economic Moat
3 days agoMorningstar

All

News

Press Releases

Research Reports

GlobeNewswire
Minerva Neurosciences Announces Promotion of Geoff Race to President
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President
Benzinga
15 Stocks Moving in Friday's Pre-Market Session
Gainers Progenity, Inc. (NASDAQ: PROG) rose 33% to $2.02 in pre-market trading after jumping over 40% on Thursday. Iterum Therapeutics plc (NASDAQ: ITRM) rose 25.1% to $0.6984 in pre-market trading after dropping over 8% on Thursday. QuickLogic Corporation (NASDAQ: QUIK) rose 14.7% to $6.15 in pre-market trading. QuickLogic reported a strategic investment by current shareholders. The company said it expects Q3 revenue of $3.8 million to $3.9 million. Paltalk, Inc. (NASDAQ: PALT) rose 12.3% to $1
Benzinga
Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. Related Link: Minerva's Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning The 48-subject study met all key pharmacokinetic (PK) objectives, and the data demonstrate bioequivalence across the various formulations. The data showed comparability under the fasted condi